potential in ARþ BCa cell lines. Our studies suggest that a combination of EnzþCis may be useful in treating patients with ARþ bladder cancer.
INTRODUCTION AND OBJECTIVES:
Invasive bladder cancer has been analyzed extensively using various 'bulk' genomic and transcriptomic approaches, such as mRNA sequencing. While these studies have been useful for elucidation of bladder cancer molecular subtypes, these bulk approaches have the inherent disadvantage that non-tumor (i.e., non-urothelial) cell types may contaminate sample preparation. Indeed, contaminating, non-tumor cell types have caused mischaracterization of bladder cancer subtypes. To avoid this problem associated with bulk sequencing approaches, we sought to characterize bladder transcriptome at single cell resolution, in both disease-free and tumor-bearing bladders.
METHODS: Bladder specimen (n[12) were obtained during TURBT or radical cystectomy from chemo naïve human bladders, and samples were isolated from the tumor as well as from normal-looking tissue located at sites distant from the tumor. Other bladder samples (n[4) were isolated from tumor-free bladders in otherwise healthy donors. Bladder mucosa was minced, enzymatically dissociated into single cell suspensions, and then subjected to single cell sequencing using the emulsion-based 10X Genomics platform and analysis using the Seurat single cell mRNA sequencing analysis pipeline.
RESULTS: The predominant cell types in our samples included epithelial, mesenchymal, and immune lineages. Whereas tumor-free bladder samples contained few KRT14þ UPK3A low basal epithelial cells, invasive bladder tumors contained much more KRT14þ UPK3A low cells. In addition, the tumor-free bladder derived basal cells uniformly expressed SHH, but SHH was lost in invasive cancer, consistent with the known loss of SHH in aggressive invasive cancer. Interestingly, normal-looking tissue from invasive tumor-bearing bladders also contained a population of KRT14þ UPK3A low cells lacking SHH, suggesting that these sites distant from the tumor contained aggressively growing basal cells similar in molecular phenotype to the invasive tumor. Noninvasive tumor epithelial cells expressed UPK3A and also retained SHH expression.
CONCLUSIONS: Bladder mucosa contains a variety of cell types. The population of bladder epithelial cells in normal looking tissue from cancer-bearing bladder is substantially different from tissue from disease free bladder, containing cells with molecular characteristics typical of tumors. INTRODUCTION AND OBJECTIVES: Despite recent advances in second line therapy for patients with advanced bladder cancer, most patients eventually progress. Selection of the choice of additional therapy who have progressed despite cisplatin-based therapy and immunotherapy is difficult. Docetaxel has been tested in the 2nd line setting and is associated with a 13% response rate. In this study, we utilize a novel computer vision deep learning approach to predict sensitivity to docetaxel using gene expression microarray data.
METHODS: Drug sensitivity data and gene expression data were obtained from the genomics of drug sensitivity website (www.cancerrxgene.org). Gene expression data were mapped to chromosomal bands and the expression data were averaged over each chromosomal band. Data were then displayed as chromosomal heatmaps with a total of 22 columns where each column represented an autosome in order of increasing chromosomal number from left to right. The chromosomal maps were utilized to develop a prediction model by training a convolutional neural network with residual blocks (ResNet architecture) from the fast.ai library (www.fast.ai.com). We trained a binary image classification algorithm to distinguish the most sensitive 50% of cell lines from the least sensitive 50% of cell lines. Transfer learning was performed with weights trained on ImageNet.
RESULTS: A representative chromosomal heatmap based on gene expression is shown below. There were a total of 940 cell lines that were tested with Docetaxel derived from cancers derived from 30 anatomic locations. The deep neural network was trained using 150 epochs with a learning rate of 1.0x10-4. We were able to achieve 81% correct classification for sensitivity on the validation dataset. The sensitivity was 80% with 78% specificity. The positive predictive value was 86% with 69% negative predictive value.
CONCLUSIONS: We employ a novel computer vision approach utilizing deep learning on a visual representation of gene expression mapped to chromosomal bands. This methodology creates a genetic "fingerprint" that is robust to changes in a small number of genes. For docetaxel, we were able to achieve a high positive predictive value for drug sensitivity, which may be helpful in determining which patients to attempt this drug as second line therapy for advanced bladder cancer.
